Effects of exosomes on pre-metastatic niche formation in tumors.
Guo Y, Ji X, Liu J, Fan D, Zhou Q, Chen C, Wang W, Wang G, Wang H, Yuan W, Ji Z, Sun Z, Sun Z. · 2019
Read Effects of exosomes on pre-metastatic niche formation in tumors. by Guo Y, Ji X, Liu J, Fan D, Zhou Q, Chen C, Wang W, Wang G, Wang H, Yuan W, Ji Z, Sun Z, Sun Z. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6413442.txt.
Introduction
Guo and co-authors review exosomes and pre-metastatic niches in Molecular Cancer. Before cancer spreads, its home tumor prepares distant organs for arrival. Those prepared spots are called pre-metastatic niches.
Exosomes, tiny vesicles shed by tumors, do much of the preparing. They stir inflammation, grow blood vessels, and weaken immune guard at the target organ. They also carry PD-L1, which helps tumor cells escape immunity. The review sorts these effects and their order. Exosome signals in blood may one day warn where a cancer plans to spread.
Catalog record
| CREATOR | Guo Y, Ji X, Liu J, Fan D, Zhou Q, Chen C, Wang W, Wang G, Wang H, Yuan W, Ji Z, Sun Z, Sun Z. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Effects of exosomes on pre-metastatic niche formation in tumors By Yaxin Guo, Xiang Ji, Jinbo Liu, Dandan Fan, Quanbo Zhou, Chen Chen, Weiwei Wang, Guixian Wang, Haijiang Wang, Weitang Yuan, Zhenyu Ji, Zhenqiang Sun Published in: Molecular Cancer DOI: 10.1186/s12943-019-0995-1 ABSTRACT Abstract A pre-metastatic niche is a microenvironment prepared for the colonization of circulating tumor cells in specific organs. Exosomes are extracellular vesicles with a variety of biological functions. Exosomes play an irreplaceable role in the development of pre-metastatic niches, and mainly function as communication medium. In this review, we analyzed the effects of exosomes on pre-metastatic niches from various perspectives, including inflammation, immune response, angiogenesis, organotropism, matrix remodeling and biomarker expression. In particular, exosomes express programmed death ligand 1 (PD-L1) and cause the immune escape of tumor cells. The immunomodulatory effects of exosomes and their potential in liquid diagnosis have drawn our attention. The potential value of exosomes and pre-metastatic niches will be realized in the field of immunity therapy. Keywords: Exosomes, Pre-metastatic niche, Tumor microenvironment, Immunoregulation, Biomarker BACKGROUND Tumor metastasis usually indicates a poor prognosis and is the leading cause of cancer-related death [1]. Thus, meaningful research is being done on how to prevent tumor metastasis. In recent years, the concept of a pre-metastatic niche has provided new ideas to prevent tumor metastasis. The pre-metastatic niche refers to the microenvironment, which is well prepared for tumor cells to colonize in and disseminate to distant organ sites. Lyden firstly proposed the idea of the pre-metastatic niche [2]. The significance of the pre-metastatic niche has received increasing attention in recent years [3, 4]. Cao summarized the characteristics and four stages of the pre-metastatic niche. The key components of the pre-metastatic niche include tumor-derived secreted factors (TDSFs), extracellular vesicles (EVs), bone marrow-derived cells (BMDCs), suppressive immune cells and host stromal cells [5]. Exosomes are extracellular vesicles with a diameter of 30–150 nm [6–8]. Exosomes were found in blood, urine, saliva and other bodily fluids [9]. As a key player in intercellular communication, exosomes transmit information through their cargo levels, including proteins, lipids, DNA, messenger RNA and microRNAs [10–15]. Exosome-mediated intercellular communication mainly occurs in the following three ways: First, the exosome membrane protein can bind to the target cell membrane protein, thereby activating the signal pathway in the target cell. Second, in the extracellular matrix, a protease cleaves the exosome membrane protein, which then binds to receptors on the cell membrane to activate the signaling pathway within the cell. Third, the exosome membrane can directly fuse with the target cell membrane, causing nonselective release of the proteins, mRNA and microRNA of the exosomes [16, 17]. Recently, reports have shown that the formation of a pre-metastatic niche depends on tumor-derived exosomes [2, 12, 18–20]. The function of exosomes depends on the type of cells from which they are derived [21, 22]. Studies have shown that tumor-derived exosomes are involved in the exchange of genetic information between tumor cells and basal cells, resulting in the production of a large number of new blood vessels, which promotes tumor growth and invasion [23, 24]. This article summarizes the role of exosomes in the pre-metastasis niche, to identify new means of cancer immunotherapy. Screening for biomarkers contained within exosomes can provide diagnostic and prognostic value. EXOSOMES PROMOTE THE UPREGULATION OF INFLAMMATORY MOLECULES IN THE PRE-METASTATIC NICHE Chronic inflammation is a driving force for tumor development and metastasis. Thus, the local inflammatory microenvironment is one of the basic factors for the formation of a pre-metastatic niche. Hoshino reported the regulatory effect of integrins (ITGs) on the proinflammatory factor S100. They identified differentially expressed genes (DEGs) by RNA sequencing in Kupffer cells (KCs) treated with different cell-derived exosomes. The results showed that S100A8 and S100P were upregulated more than four-fold after treatment with BxPC-3-LiT exosomes compared to exosomes produced by BxPC-3-LiT ITGβ5KD (BxPC-3-LiT cells with knocked down ITGβ5 expression). After treatment of WI-38 fibroblasts with 4175-LuT exosomes, S100A4, S100A6, S100A10, S100A11, S100A13 and S100A16 were upregulated five-fold compared to the 4175-LuT ITGβ4KD (4175-LuT cells with knocked down ITGβ4 expression) exosomes. Thus, exosome integrins could upregulate the expression of proinflammatory S100 molecules in the distant tissue microenvironment. How do tumor-derived exosomes upregulate the expression of proinflammatory S100? The activation of Src, and its subsequent phosphorylation, may be the main pathway [25]. The local inflammatory microenvironment can induce tumor cells to produce tumor-derived secreted factors (TDSFs), such as vascular endothelial growth factor (VEGF), tumor necrosis factor alpha (TNF-α), transforming growth factor-β (TGF-β) and interleukin (IL). These TDSFs in turn affect myeloid cells through paracrine means to stimulate their migration to future pre-metastatic niche formation sites [26]. Under the stimulation of TDSFs, host stromal cells in the pre-metastatic niche may upregulate the expression of inflammatory factors. BMDCs or immune cells are recruited to the pre-metastatic niche and accelerate the secretion of inflammatory factors. In addition, tumor-derived exosomes carry inflammatory factors into the bloodstream, which in turn reach the pre-metastatic niche. Through the above possible ways, an inflammatory microenvironment favorable for tumors is finally formed in the pre-metastatic niche. EXOSOMES INDUCE IMMUNE SUPPRESSION OR IMMUNE SURVEILLANCE IN THE PRE-METASTATIC NICHE Immune escape induced by exosome-derived PD-L1 In recent years, programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) have attracted much attention. PD-1 is mainly expressed on macrophages, activated T cells and B cells, while PD-L1 is highly expressed in tumor tissues, tumor-associated antigen-presenting cells (APCs) and stromal cells [27–30]. Under normal circumstances, T cells can recognize and attack tumor cells. However, when PD-1 binds to PD-L1, it provides an inhibitory signal, induces T cell apoptosis and inhibits T cell activation and proliferation. Therefore, blocking the PD-1/PD-L1 pathway can enhance the killing effect of T cells and improve the immune response [31, 32]. Currently, immunotherapy with PD-1/PD-L1 inhibitors has moved from the laboratory to clinical applications. Anti-PD-1/PD-L1 antibodies have fewer adverse effects than conventional radiotherapy and chemotherapy. More importantly, the patient’s remission period was longer after immunotherapy. Anti-PD-1 antibodies have shown reliable effects in clinical treatment [33]. However, patients treated with PD-1/PD-L1 inhibitors have significant individual differences [34, 35]. Studies have shown that patients with high expression of PD-L1 have better clinical efficacy with PD-1/PD-L1 blockers [36]. Researchers demonstrated that histone deacetylase (HDAC) inhibitors combined with anti-PD-1 immunotherapy enhanced the therapeutic efficiency in a melanoma mouse model [37]. Therefore, the direction of future research is how to improve the remission rate, expand the indications for anti-PD-1/PD-L1 antibodies, and reduce adverse reactions. Recently, scientists have confirmed that cancer cells release exosomes carrying PD-L1, which spread directly from the tumor tissue to all parts of the body and comprehensively crack down on and suppress the human immune system. PD-L1 in exosomes has the same structure as it does on the surface of tumor cells and can also bind to PD-1 on T cells. Cell experiments showed that exosomes incorporated with PD-L1 can inhibit the proliferation of CD8+ T cells (Fig. 1). In mouse experiments, exosomes carrying PD-L1 promoted tumor growth and reduced the number of T cells in the spleen and lymph nodes [38]. Therefore, when the exosomes carrying PD-L1 reach the pre-metastatic microenvironment, the immune system is inhibited here, and the development of the pre-metastatic niche is promoted. [Figure: Exosome PD-L1